coordinating solvent (DMF) only the R-methylproline prod-
ucts were observed (Scheme 3). And while the TES protected
Scheme 3. Cyclization of Unprotected Hydroxy Substrates
with LiHMDS
Figure 2. Possible cyclizations of the unprotected chlorohydrin.
resulting epoxyenolate (X) could then undergo either exo
closure to the azetidine (path a) or endo to the pyrrolidine
(path b).18
When the two unprotected chlorohydrins were exposed
to excess KHMDS in toluene at -60 °C, the epoxides were
the only identifiable products (Scheme 2). The proton and
Scheme 2. KHMDS Treatment of Unprotected Hydroxy
Compounds
(2S,4S) diastereomer 12 gave a 1:1 mixture of products 16
and 17 (eq 4), the unprotected hydroxyl compound 11 gave
almost exclusively the expected (2R,4R) product 16. Surpris-
ingly, when the (2S,4R) isomer 8 was cyclized, the major
product was not the expected (2R,4S) isomer, but rather the
(2S,4S), where the carboxylate bearing stereocenter has been
inverted.
During the course of the reaction we observed (by HPLC)
what appeared to be the epoxide, but it is not clear if this is
a true intermediate, or an artifact of our sample preparation
and analysis. When authentic epoxide was treated with
LiHMDS in THF, even in the presence of excess LiCl, no
reaction was observed.
As suggested by Kawabata,14 we believe that where
retention of configuration is observed (Scheme 4, path A),
deprotonation and cyclization occur from the shown con-
carbon NMR spectra of compounds 19 and 20 are virtually
indistinguishable, suggesting that scrambling occurred at
C2.
Interestingly, when the base was switched to LiHMDS (1
M in THF) and the chlorohydrin substrate dissolved in a
(6) Nagumo, S.; Mizukami, M.; Akutsu, N.; Nishida, A.; Kawahara, N.
Tetrahedron Lett. 1999, 40, 3209-3212.
(7) Sato, T.; Kawasaki, S.; Oda, N.; Yagi, S.; Bialy, S.; Uenishi, J.;
Yamauchi, M.; Ikeda, M. J. Chem. Soc., Perkin Trans. 1 2001, 2623-
2631.
Scheme 4. Possible Mechanism for Stereoselective
Cyclizations
(8) Seebach, D.; Weber, T. HelV. Chim. Acta 1985, 68, 155-161.
(9) Remuzon, P.; Bouzard, D.; Guiol, C.; Jaquet, J.-P. J. Med. Chem.
1992, 35, 2898-2909.
(10) Remuzon, P.; Massoudi, M.; Bouzard, D.; Jaquet, J.-P. Heterocycles
1992, 34, 679-684.
(11) Fuji, K.; Kawabata, T. Chem. Eur. J. 1998, 4, 373-376.
(12) Kawabata, T.; Fuji, K. Top. Stereochem. 2003, 23, 175-205.
(13) Zhao, H.; Hsu, D. C.; Carlier, P. R. Synthesis 2005, 1-16.
(14) Kawabata, T.; Kawakami, S.; Majumdar, S. J. Am. Chem. Soc. 2003,
125, 13012-13013.
(15) (a) Bergeron, R.; Xia, M.; Phanstiel, O. J. Org. Chem. 1993, 58,
6804-6806. (b) Morie, T.; Kato, S.; Harada, H.; Matsumoto, J. Heterocycles
1994, 38, 1033-1040.
(16) For a discussion of the critical nature of the nitrogen protecting
group on preservation of chirality during enolate formation and cyclization
see: (a) Kawabata, T.; Wirth, T.; Yahiro, K.; Suzuki, H.; Fuji, K. J. Am.
Chem. Soc. 1994, 116, 10809-10810. (b) Kawabata, T.; Suzuki, H.; Nagae,
Y.; Fuji, K. Angew. Chem., Int. Ed. 2000, 39, 2155-2157. (c) Kawabata,
T.; Chen, J.; Suzuki, H.; Nagae, Y.; Kinoshita, T.; Chancharunee, S.; Fuji,
K. Org. Lett. 2000, 2, 3883-3885.
Org. Lett., Vol. 9, No. 16, 2007
3031